On the heels of a surprise trial failure for Eli Lilly’s soft tissue sarcoma drug Lartruvo, European officials have barred new patients, putting the drug’s future in jeopardy there. And they released survival numbers from that trial that Lilly hadn’t
read moreWhen the dust settles on the fourth quarter, analysts expect Merck’s Keytruda to maintain its lead over archrival Opdivo from Bristol-Myers Squibb. But it’s Opdivo that could surprise Wall Street, one analyst says. More: Look out for a Q4 surprise
read moreBetween President Trump on Twitter and critics in Congress, pharma and its pricing faced daily fire last year. But the industry’s top lobbyists shot back—and shelled out a record amount of cash to do it. More: As drug prices took
read moreA 15-year-old boy with a rare brain tumour is set to begin innovative treatment at the NHS’s new Proton Beam Therapy centre, at The Christie hospital in Manchester. More: 15-year-old brain cancer patient to receive specialist radiotherapy Source: News
read moreThe National Institute for Health and Care Excellence (NICE) has recommended digital cognitive behavioural therapy for use on the NHS in children and young people with mild depression. More: NICE backs digital CBT for mildly depressed children and young people
read moreNovo Nordisk has announced that Ozempic, a new once-weekly GLP-1 (human glucagon-like peptide-1) analogue injection for the treatment of type II diabetes, is now available in the UK. More: Ozempic launched for type II diabetes in the UK Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals